



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Gregory Riely, M.D., Ph.D.

Committee: Oncologic Drugs Advisory Committee (ODAC)

Meeting Date: July 13, 2017

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: Biologics license application (BLA) 761028 for ABP 215, a proposed biosimilar to Genentech/Roche’s AVASTIN (bevacizumab), submitted by Amgen Inc. The proposed indications/uses for this product are:(1) For the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil-based chemotherapy; (2) in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line ABP 215-containing regimen; (3) for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer in combination with carboplatin and paclitaxel; (4) for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent; (5) for the treatment of metastatic renal cell carcinoma in combination with interferon alfa; and (6) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of persistent, recurrent, or metastatic carcinoma of the cervix, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None.		
II. Other Imputed Interests		
Employer’s research contracts	(b) (4), Party to the Matter	\$300,000 – \$350,000 total
	(b) (4), Competing firm	\$100,000 – \$150,000 total
	(b) (4) Competing firm	\$3,100,000 - \$3,200,000 total
	(b) (4), Competing firm	\$850,000 - \$900,000 total
	(b) (4), Competing firm	\$0 – \$50,000 total
	(b) (4), Competing firm	\$350,000 – \$400,000 total

	(b) (4), Competing firm	\$50,001 – \$100,000 total
	(b) (4) Competing firm	\$300,000 – \$350,000 total
	(b) (4) Competing firm	\$0 – \$50,000 total
	(b) (4) Competing firm	\$200,000– \$250,000 total

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

____6/26/2017_____
Date